Aterovax SA

Aterovax is developing innovative products for the cardiovascular disease market based on a unique understanding of atherosclerosis, the condition responsible for most cardiovascular problems. Aterovax’s first product is a diagnostic blood test to measure activity of secretory phospholipase A2 (sPLA2), a powerful biomarker that provides physicians with clinically relevant information about the presence of a destabilized atherosclerotic plaque. The Company was founded in Paris, France in 2006 with financing from the SEFTI fund, a specialist European cardiovascular fund.